Poor
Not Aligned
Patient Risk:
Medium
Summary
Several safety/label-relevant claims are unsupported or likely inaccurate relative to the provided Stromectol (ivermectin) label excerpts (e.g., “sulfa allergy/cross-reactivity,” existence of FDA “comprehensive list,” and alternatives in sulfa allergy). While the label excerpts do support ivermectin indications, contraindication to hypersensitivity to product components, dosing by body weight, key warnings (neurotoxicity/Loa loa), and warfarin/INR interaction, those are not the claims being evaluated here and the questionable content materially reduces alignment.
Category Scores
Accurate Statements
Ivermectin is an antiparasitic medication used to treat various infections, including river blindness, strongyloidiasis, and scabies.
Partially supported only for strongyloidiasis and onchocerciasis (river blindness) in provided label excerpts (1 INDICATIONS AND USAGE). No provided label support for scabies.
Ivermectin is sold under the brand names Stromectol, Mectizan, and Sklice, among others.
The main ivermectin formulations are oral tablets and topical creams.
The oral tablets contain the active ingredient ivermectin.
Each tablet contains 3 mg of ivermectin (provided Stromectol tablet labeling excerpt), consistent with label excerpt reference.
Unsupported Statements
Ivermectin has been linked to sulfa allergy reactions in some cases.
No mention in the provided label excerpts regarding sulfa allergies or sulfonamide-class cross-reactivity.
The sulfonamide group is a class of antimicrobials known to cause allergic reactions in some individuals.
Not addressed in the provided Stromectol label excerpts.
In rare cases, ivermectin has been associated with cross-reactivity due to its chemical similarity to sulfonamides.
Not mentioned in the provided label excerpts.
Pharmaceutical companies are required to list potential allergens, including sulfa, on medication labels.
Not stated in the provided label excerpts.
The FDA has a comprehensive list of medications that contain sulfa, which includes ivermectin formulations.
Not addressed in the provided label excerpts.
Patients with known sulfa allergies should exercise caution when using ivermectin.
No sulfa-allergy caution language appears in the provided label excerpts. Provided contraindication is hypersensitivity to any component of the product (4 CONTRAINDICATIONS).
Other antiparasitic medications, such as albendazole and praziquantel, may be considered as alternatives for patients with sulfa allergies.
No label support for recommending alternatives based on sulfa allergy; alternatives are not discussed in provided excerpts.
Contradictions
Low
AI Statement
Ivermectin is an antiparasitic medication used to treat various infections, including river blindness, strongyloidiasis, and scabies.
Label Reference
1 INDICATIONS AND USAGE (provided excerpts list Strongyloidiasis and Onchocerciasis; NOTE: no activity against adult Onchocerca volvulus; scabies not included).
Important Omissions
No mention of key Stromectol labeling safety items such as ivermectin neurotoxicity warning and the need for pretreatment assessment for Loa loa infection in onchocerciasis patients (5 WARNINGS).
Importance:
Moderate
No mention of contraindication: hypersensitivity to any component of the product (4 CONTRAINDICATIONS).
Importance:
Moderate
No mention of ivermectin dosing by body weight for strongyloidiasis (single oral dose ~200 mcg/kg) and onchocerciasis (~150 mcg/kg) (2 DOSAGE AND ADMINISTRATION).
Importance:
Moderate
No mention of the warfarin/INR interaction reported post-marketing (DRUG INTERACTIONS).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
The response includes multiple allergy/cross-reactivity claims (sulfa allergy, FDA list, and alternative drugs) that are not supported by the provided Stromectol label excerpts and may distract from label-relevant contraindications (product component hypersensitivity) and warnings (neurotoxicity/Loa loa assessment).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple statements about “sulfa allergy” and cross-reactivity/alternatives are not supported by the provided Stromectol label excerpts.
Suggested Improvement
Limit claims to label-supported information in the provided excerpts (approved indications for strongyloidiasis and onchocerciasis; dosing by body weight; contraindication to hypersensitivity to product components; key warnings including neurotoxicity and Loa loa encephalopathy risk; and the warfarin/INR interaction). Remove unsupported sulfa-allergy and FDA-list statements unless supported by the provided label text.